Playbooks, reviewer perspectives, templates and demos.

AMNOG dossier

Map the comparator, draft the clinical benefit narrative against G-BA expectations, and source every claim back to the trial publication, label or SmPC.

NICE submission

Build a NICE company evidence submission against the reference case: ITCs pre-checked, model inputs reproducible, every assumption traceable.

HAS / G-BA response

Pull every relevant comparator readout, precedent decision and methodological objection into one workspace.

Payer objection handling

Run the value story against every objection a payer has raised against similar assets in the last 36 months — and draft the response.

Price & access simulation

Model the realistic pricing corridor given the HTA outcome you're most likely to get and the international reference pricing knock-ons.

Rapid literature review

Structured search across PubMed, Embase, congress abstracts and HTA decisions, deduplicated and screened with reviewer-grade criteria.

Indirect treatment comparison

Scaffold anchored and unanchored MAICs, NMAs and standard ITCs — assumptions tracked, sensitivity pre-run, code your ERG or IQWiG can reproduce.

Systematic review

Pre-registered protocols, dual screening, structured extraction, risk-of-bias assessment and PRISMA-compliant reporting.

Real-world evidence

Synthesise registry, claims and chart-review evidence into a defensible RWE story — biases captured, limitations addressed up front.

Medical Information & SRD

Draft SRDs against the label, the trial and the published literature — every claim sourced, off-label flagged, MLR-ready formatting baked in.

Congress prep

Scan abstracts the moment they drop, map readouts to your value story, and refresh the MSL deck, access pack and rebuttal library.

Launch readiness

A continuously refreshed launch-readiness map — competitor pipeline, HTA precedent, payer mix, KOLs, RWE and field readiness.

Competitive intelligence

A continuously refreshed view of every competitor — pipeline, readouts, label changes, HTA decisions, KOL voice and pricing trajectory.

Investor narrative

Build the value narrative on the same evidence base your CMO uses for the dossier — defensible, comparable-anchored, ready for diligence.

BD & licensing diligence

Map the target's clinical position, competitor landscape, HTA precedent, pricing corridor and deal comparables in one workspace.

Pipeline prioritisation

Score every asset and indication against competitor pipeline, HTA precedent, addressable population and pricing corridor.